Fig. 1

a–d, f Volcano plots of lipidomic data for wnt5b morphants compared to control embryos at gastrula stage (6hpf at 28 °C) from four independent experiments. Horizontal dashed line thresholds significance (p-value = 0.05). NS (statistically non-significant); S (statistically significant). Unpaired, two-tailed student’s t-test was used. Blue shadowed area delimits +/−1.5-fold difference in abundance with respect to control. Relevant changes in the decrease of the content of a lipid species are located in the upper left quadrant. Each dot corresponds to an individual lipid species. a, c Sphingolipids in deyolked wnt5b morphant embryos (a) or in the yolk cell of wnt5b MO-injected embryos (c). Blue dots correspond to ceramides (Cer), red to Hexosylceramides (HexCer) and yellow to sphingomyelin (SM). b, d Phospholipids (PC, PE, PI, and PS) in deyolked wnt5b morphant embryos (b) or in the yolk cell of wnt5b MO-injected embryos (d). Note that the phospholipids significantly downregulated or upregulated beyond 1.5-fold in b and d correspond to phospholipids present at very low levels (between 1.3 x 10⁻³ and 8.4 x 10⁻⁷ Mol%) and therefore their amounts cannot be precisely determined in control versus wnt5b morphant conditions. e Simplified scheme representing both the de novo and salvage pathways for sphingolipid biosynthesis, with selected metabolites and genes indicated. DHCer dihydroceramide, HexDHCer dihydrohexosylceramide, DHSM dihydrosphingomyelin. f Volcano plot for sphingolipids in the de novo pathway in wnt5b deyolked morphant embryos. Lipid amounts are normalized as pmol/nmol inorganic phosphate (see “Methods”). Source data are provided as a Source Data file.